About
Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalStem Cell & Cellular TherapyAntibodyBiotech
Clinical Trials (13)
View allTotal Trials
13
As Lead Sponsor
6
As Collaborator
7
Total Enrollment
155
By Phase
EARLY_PHASE1: 5PHASE1/PHASE2: 2PHASE2: 1PHASE1: 5
By Status
TERMINATED: 4RECRUITING: 3UNKNOWN: 3COMPLETED: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline13 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07168291Collaborator
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
EARLY_PHASE1Not yet recruiting
3 participants
Started: Dec 31, 2025 · Completed: Dec 31, 2028
NCT06343311Collaborator
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
PHASE1/PHASE2Recruiting
21 participants
Started: Jun 1, 2024 · Completed: Dec 31, 2027
NCT04634357Lead Sponsor
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
PHASE1/PHASE2Recruiting
15 participants
Started: Jul 19, 2022 · Completed: Jan 31, 2028
NCT04864054Lead Sponsor
T-Cell Therapy (ECT204) in Adults With Advanced HCC
PHASE2Recruiting
20 participants
Started: Mar 11, 2022 · Completed: Dec 31, 2027
NCT04502082Lead Sponsor
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
PHASE1Terminated
8 participants
Started: Apr 14, 2021 · Completed: Aug 30, 2024
Locations (1)
Headquarters
Emeryville, CA, United States
Map
Loading map...